Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1994-04-25
1996-02-20
Jordan, Kimberly R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
514879, A61K 3127
Patent
active
054929300
ABSTRACT:
A method for treating CNS disorders and/or improving cognitive ability in a mammal utilizing 2-phenyl-1,3-propanediol monocarbamate is disclosed. Also disclosed are formulations and methods for manufacturing this compound.
REFERENCES:
patent: 3812263 (1974-05-01), Gilbertson
patent: 4868327 (1989-09-01), Stiefel
patent: 4978680 (1990-12-01), Sofia
patent: 4982016 (1991-01-01), Choi
patent: 5055489 (1991-12-01), Sofia
patent: 5072056 (1991-12-01), Stiefel
patent: 5082861 (1992-01-01), Sofia
Metabolites of Felbamate Synthesis of 2(4-hydroxyphenyl)-1,3-propanediol dicarbamate, 2-phenyl-2-hydroxy-1,3-propanediol dicarbamate, and 2-phenyl-1,3-propanediol monocarbamate, Tetrahedron Letters, vol. 42, No. 23, Y. M. Choi, et al., Pergamon Journals, Ltd., pp. 6399-6404 (1986).
Drugs of the Future, vol. 11, No. 11, pp. 931-932 (1986).
Comparative Anticonvulsant Activity and Neurotoxicity of Felbamate and Four Prototype Anti-epileptic Drugs in Mice and Rats, E. A. Swinyard et al., Epilepsia, vol. 27, pp. 27-34 Raven Press (1986).
A Neuropharmacological Evaluation of Felbamate as a Novel Anticonvulsant, H. S. White, et al., Epilepsia, vol. 33(3), pp. 564-572 Raven Press (1992).
Evidence for Anticonvulsant and Neuroprotectant Action of Felbamate Mediated by Strychnine-Insensitive Glycine Receptors, R. T. McCabe, et al., The Journal of Pharmacology and Experimetnal Therapeutics, vol. 264, No. 3 pp. 1248-1252 (1993).
Felbamate is a Potent Anti-Hypoxic Agent in the Hippocampal Slice, R. A. Wallis, et al., Neurology 40 (Suppl. 1) pp. 193 No. 2775 (Apr. 1990).
Glycine Prodrug Facilitates Memory Retrieval in Humans, B. L. Schwartz, et al., Neurology 41, (Sep., 1991) pp. 1341-1343.
Excitatory Amino Acids and Memory; Evidence from Research on Alzheimer's Disease and Behavioral Pharmacology, C. Advokat et al., Neuroscience and Behavioral Reviews vol. 16 pp. 13-24 (1992).
Competitive Antagonism of Glycine at the N-Methyl-D-Asparate (NMDA) Receptor, J. E. Huettner. Biochemical Pharmacology, vol. 41, No. 1, pp. 9-16 (1991).
Jordan Kimberly R.
Mazer Edward H.
Schering Corporation
LandOfFree
Method and formulation for treating CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and formulation for treating CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and formulation for treating CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1356145